Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:2526 |
Name | prostate adenocarcinoma |
Definition | A prostate carcinoma that derives_from epithelial cells of glandular origin. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer male reproductive organ cancer prostate cancer prostate carcinoma prostate adenocarcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
PTEN inact mut | XL147 | prostate adenocarcinoma | sensitive | detail... |
PTEN inact mut | Paclitaxel + XL147 | prostate adenocarcinoma | sensitive | detail... |
ATM L1449* | Olaparib | prostate adenocarcinoma | predicted - sensitive | detail... |
BRAF K601E | Trametinib | prostate adenocarcinoma | no benefit | detail... |
MLH1 negative | Pembrolizumab | prostate adenocarcinoma | sensitive | detail... |
MSH6 negative | Pembrolizumab | prostate adenocarcinoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00002651 | Phase III | Bicalutamide Goserelin | Hormone Therapy in Treating Men With Stage IV Prostate Cancer | Completed | CAN | 0 |
NCT00223665 | Phase II | Leuprolide Flutamide | Intermittent Hormone Therapy in Men With Localized Prostate Cancer After Radiation Therapy or Radical Prostatectomy | Completed | USA | 0 |
NCT00268476 | Phase II | Abiraterone + Prednisolone Metformin Abiraterone + Enzalutamide + Prednisolone Celecoxib Estradiol Zoledronic acid Docetaxel + Prednisolone Docetaxel + Prednisolone + Zoledronic acid Celecoxib + Zoledronic acid | Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) | Active, not recruiting | GBR | 1 |
NCT00303784 | Phase III | Estradiol Goserelin | Prostate Adenocarcinoma TransCutaneous Hormones (PATCH) | Unknown status | GBR | 0 |
NCT00536991 | Phase Ib/II | Prednisone Calcitriol Ketoconazole | Calcitriol, Ketoconazole, and Hydrocortisone in Treating Patients With Advanced or Recurrent Prostate Cancer | Terminated | USA | 0 |
NCT00541047 | Phase III | Leuprolide Goserelin Bicalutamide | Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS) | Unknown status | GBR | CAN | 0 |
NCT00589420 | Phase II | Docetaxel + Sorafenib | Sorafenib and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy | Completed | USA | 0 |
NCT00720785 | Phase I | Bortezomib | Natural Killer Cells and Bortezomib to Treat Cancer | Completed | USA | 0 |
NCT00859781 | Phase II | Prednisone Ketoconazole | 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer | Active, not recruiting | USA | 0 |
NCT00936390 | Phase III | Flutamide Goserelin Leuprolide Triptorelin Bicalutamide | Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer | Active, not recruiting | USA | CAN | 0 |
NCT01174199 | Phase I | Temsirolimus + Vorinostat | Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer | Terminated | USA | 0 |
NCT01313559 | Phase II | Everolimus + Pasireotide Pasireotide | Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer | Terminated | USA | 0 |
NCT01342367 | Phase I | Bicalutamide Dutasteride Finasteride | Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer | Active, not recruiting | USA | 0 |
NCT01409200 | Phase II | Axitinib | Neoadjuvant Axitinib in Prostate Cancer | Active, not recruiting | USA | 0 |
NCT01420250 | Phase I | Bicalutamide Cabazitaxel | Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer | Active, not recruiting | USA | 0 |
NCT01485861 | Phase II | Apitolisib Abiraterone Ipatasertib | Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy | Completed | USA | ITA | GBR | FRA | ESP | 4 |
NCT01498978 | Phase II | Ipilimumab | Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | Completed | USA | 0 |
NCT01503229 | Phase II | Prednisone Abiraterone | Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | Completed | USA | 0 |
NCT01513733 | Phase I | Tasquinimod Cabazitaxel | The CATCH Prostate Cancer Trial Cabazitaxel And Tasquinimod in Men With Prostate Cancer | Completed | USA | 0 |
NCT01548807 | Phase I | Everolimus | Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy | Completed | USA | 0 |
NCT01560923 | Phase II | Sipuleucel-T | Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer | Completed | USA | 0 |
NCT01619813 | Phase II | Docetaxel + Prednisone Pelareorep | Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer | Completed | CAN | 0 |
NCT01630590 | Phase II | Cabozantinib | Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer | Completed | USA | 0 |
NCT01681433 | Phase II | Prednisone Abiraterone Apatorsen | OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone | Terminated | USA | CAN | 0 |
NCT01688492 | Phase Ib/II | Abiraterone + Prednisone Ipilimumab | Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer | Active, not recruiting | USA | 0 |
NCT01695473 | Phase II | Buparlisib | Neoadjuvant BKM120 in High-risk Prostate Cancer | Terminated | USA | 0 |
NCT01703065 | Phase I | Cabozantinib | Cabozantinib in Treating Men With Castration-Resistant Prostate Cancer | Terminated | USA | 0 |
NCT01706458 | Phase II | pTVG-HP plasmid DNA vaccine Sipuleucel-T | Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer | Completed | USA | 0 |
NCT01709734 | Phase II | Galeterone | A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer | Terminated | USA | CAN | 0 |
NCT01786265 | Phase II | Goserelin Degarelix Abiraterone Prednisone Leuprolide | Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone | Active, not recruiting | USA | 0 |
NCT01787331 | Phase II | Itraconazole | A Phase II Study of Itraconazole in Biochemical Relapse | Completed | USA | 0 |
NCT01790126 | Phase II | Apalutamide | The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer | Completed | USA | 0 |
NCT01804465 | Phase II | Ipilimumab | A Randomized Phase 2 Trial of Combining Sipuleucel-T With Immediate vs. Delayed CTLA-4 Blockade for Prostate Cancer | Completed | USA | 0 |
NCT01807065 | Phase II | Sipuleucel-T | Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer | Completed | USA | 0 |
NCT01812668 | Phase I | Cabozantinib | Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer | Completed | USA | 0 |
NCT01832259 | Phase II | Pazopanib | A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection | Completed | USA | 0 |
NCT01845792 | Phase II | Cabazitaxel Abiraterone | Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer | Terminated | USA | 0 |
NCT01848067 | Phase Ib/II | Abiraterone Prednisone Alisertib | Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer | Completed | USA | 0 |
NCT01885949 | Phase II | Enzalutamide + Tivozanib | Tivozanib + Enzalutamide in Adv Prostate Cancer | Active, not recruiting | USA | 0 |
NCT01927627 | Phase II | Enzalutamide | Enzalutamide in Patients With High-risk Prostate Cancer | Completed | USA | 0 |
NCT01940276 | Phase II | Abiraterone + Prednisone | Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer | Completed | USA | 0 |
NCT01942837 | Phase II | Enzalutamide | Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer With Correlative Assessment of Androgen Receptor Signaling | Completed | USA | 0 |
NCT01946204 | Phase III | Apalutamide | A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer (SPARTAN) | Active, not recruiting | USA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 16 |
NCT01949337 | Phase III | Abiraterone Prednisone Enzalutamide | Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer | Active, not recruiting | USA | CAN | 1 |
NCT01961843 | Phase I | Prednisone Abiraterone | Abiraterone Acetate for Castrate Resistant Prostate Cancer | Unknown status | USA | 0 |
NCT01977651 | FDA approved | Enzalutamide | A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 11 |
NCT01996696 | Phase II | Metformin | A Study With or Without Metformin to Determine if Metformin Can Prevent Weight Gain and Other Problems (i.e. Diabetes, Increased Cholesterol, Etc.) That Can Arise From the Use of Hormonal Therapy in Combination With Radiation Therapy When Treating Aggressive Localized Prostate Cancer. | Unknown status | CAN | 0 |
NCT02003924 | Phase III | Enzalutamide | Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 22 |
NCT02023463 | Phase I | Goserelin Enzalutamide Leuprolide | Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer | Active, not recruiting | USA | 0 |
NCT02025010 | Phase II | Abiraterone | Phase II Clinical Trial of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer With Correlative Assessment of Hormone Intermediates. | Active, not recruiting | USA | 0 |
NCT02034552 | Phase II | Prednisone Radium Ra 223 dichloride Enzalutamide Abiraterone | A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC) | Completed | USA | 0 |
NCT02036918 | Phase I | Sipuleucel-T | Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer | Completed | USA | 0 |
NCT02043678 | Phase III | Prednisone Abiraterone Radium Ra 223 dichloride | Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 10 |
NCT02057939 | Phase II | Enzalutamide Leuprolide | Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM) | Completed | USA | 0 |
NCT02058706 | Phase II | Goserelin Bicalutamide Enzalutamide Leuprolide | LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer | Completed | USA | 0 |
NCT02064036 | Phase I | Bicalutamide Goserelin Leuprolide | Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate | Completed | USA | 0 |
NCT02064582 | Phase II | Leuprolide Enzalutamide | Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer | Completed | USA | 0 |
NCT02090114 | Phase II | Testosterone Abiraterone Enzalutamide | RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistant (The RESTORE Study) | Completed | USA | 0 |
NCT02099864 | Phase II | Enzalutamide | Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy | Active, not recruiting | USA | 0 |
NCT02106507 | Phase I | Apalutamide + Everolimus | ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate | Completed | USA | 0 |
NCT02111187 | Phase I | Sonidegib | A Pre-surgical Study of LDE225 in Men With High-risk Localized Prostate Cancer | Completed | USA | 0 |
NCT02123758 | Phase I | Abiraterone + Apalutamide + Prednisone | A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer | Active, not recruiting | USA | GBR | CAN | 1 |
NCT02125084 | Phase I | Enzalutamide + Everolimus | Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer | Completed | USA | 0 |
NCT02125357 | Phase II | Enzalutamide Abiraterone | Sequencing Abiraterone and Enzalutamide in mCRPC | Completed | CAN | 0 |
NCT02146833 | Phase II | Selinexor | Study of Selinexor (KPT-330) in Metastatic Castrate Resistant Prostate Adenocarcinoma | Terminated | USA | 0 |
NCT02176161 | Phase II | Metformin | Metformin Prostate Cancer Adjuvant Trial | Completed | USA | 0 |
NCT02182622 | Phase I | Docetaxel Sonidegib | LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel | Withdrawn | USA | 0 |
NCT02194842 | Phase III | Enzalutamide Enzalutamide + Radium Ra 223 dichloride | Phase III Radium 223 mCRPC-PEACE III (PEACE III) | Active, not recruiting | ITA | GBR | FRA | ESP | CAN | BEL | 6 |
NCT02199197 | Phase II | Enzalutamide | Radium Ra 223 With Enzalutamide in Men With Metastatic Castration Refractory Prostate Cancer | Completed | USA | 0 |
NCT02200614 | Phase III | Darolutamide | Efficacy and Safety Study of ODM-201 in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 26 |
NCT02203695 | Phase II | Enzalutamide | Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy | Active, not recruiting | USA | 0 |
NCT02204072 | Phase I | Enzalutamide Xentuzumab | BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC) | Active, not recruiting | USA | GBR | ESP | 5 |
NCT02207504 | Phase I | Crizotinib + Enzalutamide | Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer | Completed | USA | 0 |
NCT02213107 | Phase II | Dutasteride + Enzalutamide | Enzalutamide & Dutasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer. | Active, not recruiting | USA | 0 |
NCT02215096 | Phase I | Enzalutamide GSK2636771 | Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer | Completed | USA | GBR | 0 |
NCT02215161 | Phase II | Selinexor | Selinexor (KPT-330) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Prior Therapy With Abiraterone and/or Enzalutamide | Terminated | USA | 0 |
NCT02217566 | Phase II | Abiraterone | Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy | Completed | 1 | |
NCT02217709 | Phase II | Phenelzine | Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer | Completed | USA | 0 |
NCT02254785 | Phase II | Abiraterone Enzalutamide Cabazitaxel | Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer | Unknown status | CAN | AUS | 0 |
NCT02256111 | Phase II | Enzalutamide | EXTEND Exercise Trial | Completed | USA | 0 |
NCT02257736 | Phase III | Abiraterone + Apalutamide Abiraterone | An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) | Active, not recruiting | USA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 8 |
NCT02262910 | Phase I | MOR209/ES414 | Study of MOR209/ES414 in Metastatic Castration-Resistant Prostate Cancer | Completed | USA | AUS | 0 |
NCT02268175 | Phase II | Enzalutamide Abiraterone Prednisone Leuprolide | Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate | Completed | USA | 0 |
NCT02284971 | Phase I | Varlilumab | Pilot Study of SBRT and CDX-1127 in Prostate Cancer (Prostate-04) | Terminated | USA | 0 |
NCT02286921 | Phase II | Enzalutamide Testosterone | Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance | Completed | USA | 0 |
NCT02303327 | Phase III | Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients | Recruiting | CAN | 0 | |
NCT02319837 | Phase III | Leuprolide Enzalutamide | Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | CAN | AUT | AUS | 9 |
NCT02346253 | Phase Ib/II | Leuprolide Triptorelin Degarelix Bicalutamide Goserelin | High-Dose Brachytherapy in Treating Patients With Prostate Cancer | Active, not recruiting | USA | 0 |
NCT02349139 | Phase Ib/II | ASN001 | Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer | Terminated | USA | 0 |
NCT02353715 | Phase I | Abiraterone Enzalutamide Sipuleucel-T | Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge), Abiraterone Acetate (Zytiga) or Enzalutamide (Xtandi) Undergoing Cardiopulmonary EXercise Testing | Completed | USA | 0 |
NCT02376166 | Phase I | Metformin | Metformin for Rising PSA Remote Trial | Completed | USA | 0 |
NCT02379390 | Phase II | Prednisone Abiraterone Enzalutamide Cabazitaxel | Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enz (PRIMCAB) | Terminated | USA | CAN | 0 |
NCT02381236 | Phase II | Mipsagargin | G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer | Completed | USA | 0 |
NCT02384382 | Phase II | Enzalutamide | A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC) | Completed | USA | 0 |
NCT02396368 | Phase I | Tasquinimod Radium Ra 223 dichloride | A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer | Withdrawn | USA | 0 |
NCT02407054 | Phase II | Enzalutamide LY3023414 | A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer | Completed | USA | 0 |
NCT02411786 | Phase I | pTVG-AR Sargramostim | A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF | Completed | USA | 0 |
NCT02415621 | Phase I | Abiraterone | Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer | Active, not recruiting | USA | 0 |
NCT02441517 | FDA approved | Enzalutamide | A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel Treatment in Patients Who Have Previously Received Enzalutamide | Terminated | USA | 0 |
NCT02446405 | Phase III | Enzalutamide | Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer | Active, not recruiting | USA | GBR | CAN | AUS | 2 |
NCT02446444 | Phase III | Enzalutamide | Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer | Active, not recruiting | USA | GBR | ESP | BEL | AUT | AUS | 3 |
NCT02463799 | Phase II | Radium Ra 223 dichloride Sipuleucel-T | Ph 2 Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC | Completed | USA | 0 |
NCT02472275 | Phase I | Leuprolide Pexidartinib Goserelin Degarelix | PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer | Completed | USA | 0 |
NCT02489318 | Phase III | Apalutamide | A Phase 3 Study of JNJ-56021927 Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With Low-Volume mHSPC | Active, not recruiting | USA | GBR | FRA | ESP | DEU | CAN | AUS | 15 |
NCT02491411 | Phase I | Enzalutamide Dexamethasone | Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel | Terminated | USA | 0 |
NCT02494713 | Phase II | Degarelix Estramustine Docetaxel Doxorubicin Ketoconazole | Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer | Terminated | USA | 0 |
NCT02497638 | Phase II | Atorvastatin + Metformin | LIpitor and biGuanide to Androgen Delay Trial | Withdrawn | CAN | 0 |
NCT02499835 | Phase Ib/II | Pembrolizumab | Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer | Active, not recruiting | USA | 0 |
NCT02500901 | Phase I | Niraparib Enzalutamide | Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC) | Terminated | USA | 0 |
NCT02506114 | Phase II | PROSTVAC-F-TRICOM + PROSTVAC-V-TRICOM Ipilimumab Ipilimumab + PROSTVAC-F-TRICOM + PROSTVAC-V-TRICOM | Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer | Terminated | USA | 0 |
NCT02508636 | Phase II | Enzalutamide + Leuprolide | Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate | Terminated | USA | 0 |
NCT02532114 | Phase I | Enzalutamide Niclosamide | Niclosamide and Enzalutamide in Treating Patients With Androgen Receptor Splice Variant-Positive, Castration-Resistant, Metastatic Prostate Cancer | Completed | USA | 0 |
NCT02543255 | Phase II | Cabazitaxel Abiraterone + Leuprolide + Prednisone Pegfilgrastim | Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial) | Completed | CAN | 0 |
NCT02560051 | Phase II | Degarelix Aldoxorubicin + Docetaxel + Estramustine + Ketoconazole | Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer | Terminated | USA | 0 |
NCT02578797 | Phase I | Apalutamide | A JNJ-56021927 (ARN-509) QT/QTc Study | Completed | USA | GBR | CAN | 2 |
NCT02582749 | Phase II | Bicalutamide + Radium Ra 223 dichloride Bicalutamide | Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases | Terminated | USA | 0 |
NCT02601014 | Phase II | Ipilimumab + Nivolumab | Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7 | Completed | USA | 0 |
NCT02606123 | Phase Ib/II | EPI-506 | Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer | Terminated | USA | CAN | 0 |
NCT02625857 | Phase I | JNJ-64041809 | Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer | Completed | USA | 0 |
NCT02643667 | Phase Ib/II | Ibrutinib | A Study of Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer | Active, not recruiting | USA | 0 |
NCT02655822 | Phase I | Atezolizumab + CPI-444 CPI-444 | Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers | Completed | USA | CAN | AUS | 0 |
NCT02677896 | Phase III | Enzalutamide | A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 15 |
NCT02685267 | Phase II | Docetaxel + Enzalutamide + Prednisone Docetaxel + Prednisone | Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer (Doce/Enza) | Terminated | USA | 0 |
NCT02685397 | Phase II | Enzalutamide Triptorelin Goserelin Leuprolide | Management of Castration-Resistant Prostate Cancer With Oligometastases | Recruiting | CAN | 0 |
NCT02703623 | Phase II | Ipilimumab Abiraterone + Apalutamide + Prednisone Cabazitaxel + Carboplatin | A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer (DynaMO) | Active, not recruiting | USA | 0 |
NCT02716974 | Phase I | Bicalutamide + Docetaxel + Leuprolide | A Study of Definitive Therapy to Treat Prostate Cancer | Completed | USA | 0 |
NCT02721979 | Phase II | Apalutamide | ARN-509 in Treating Patients With Prostate Cancer Who Are in Active Surveillance | Terminated | USA | 0 |
NCT02758132 | Phase I | Abiraterone + Denosumab + Enzalutamide + Prednisone Denosumab + Enzalutamide | Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases | Terminated | USA | 0 |
NCT02768363 | Phase II | AdV-tk + Valacyclovir Valacyclovir | Randomized Controlled Trial of ProstAtak Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES) | Active, not recruiting | USA | 1 |
NCT02770391 | Phase II | Apalutamide + Leuprolide | ARN-509 and Leuprolide in Intermediate and High-risk Prostate Cancer | Completed | USA | 0 |
NCT02772588 | Phase II | Abiraterone + Apalutamide + Leuprolide | AASUR in High Risk Prostate Cancer | Active, not recruiting | USA | 0 |
NCT02787005 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Chemotherapy (MK-3475-199/KEYNOTE-199) | Completed | 0 | |
NCT02788773 | Phase II | Durvalumab + Tremelimumab Durvalumab | Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer | Active, not recruiting | CAN | 0 |
NCT02793219 | Phase II | Docetaxel + Sipuleucel-T | Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer | Withdrawn | USA | 0 |
NCT02793765 | Phase II | Docetaxel + Sipuleucel-T | Docetaxel Followed by Provenge in Metastatic Prostate Cancer | Withdrawn | USA | 0 |
NCT02799602 | Phase III | Darolutamide Darolutamide + Docetaxel | ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer (ARASENS) | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 14 |
NCT02799706 | Phase III | Flutamide Degarelix Bicalutamide | Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer (PEGASUS) | Active, not recruiting | ITA | GBR | FRA | ESP | DEU | BEL | 2 |
NCT02799745 | Phase II | Enzalutamide | A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance (ENACT) (ENACT) | Completed | USA | CAN | 0 |
NCT02805894 | Phase Ib/II | NBTXR3 | NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma | Terminated | USA | 0 |
NCT02811809 | Phase II | Leuprolide Apalutamide + Leuprolide | Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer | Withdrawn | USA | 0 |
NCT02814669 | Phase I | Atezolizumab + Radium Ra 223 dichloride | Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor | Completed | USA | 0 |
NCT02849990 | Phase II | Abiraterone + Apalutamide + Degarelix + Indomethacin + Prednisone | Androgen Receptor Antagonist ARN-509, Abiraterone Acetate, Prednisone, Degarelix, and Indomethacin in Treating Patients With Localized Prostate Cancer Before Surgery | Completed | USA | 0 |
NCT02861573 | Phase I | Dexamethasone + Docetaxel + Pembrolizumab + Prednisone Olaparib + Pembrolizumab Enzalutamide + Pembrolizumab | Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) | Recruiting | USA | ITA | GBR | FRA | DEU | CAN | AUT | AUS | 12 |
NCT02893917 | Phase II | Cediranib + Olaparib Olaparib | Olaparib With or Without Cediranib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | Active, not recruiting | USA | 0 |
NCT02903160 | Phase II | Abiraterone + Cabazitaxel + Carboplatin + Enzalutamide + Prednisone | Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC) | Completed | USA | 0 |
NCT02903368 | Phase II | Abiraterone + Leuprolide + Prednisone Abiraterone + Apalutamide + Leuprolide + Prednisone | Neoadjuvant And Adjuvant Abiraterone Acetate + Aptilutamide Prostate Cancer Undergoing Prostatectomy | Active, not recruiting | USA | 0 |
NCT02905318 | Phase II | Palbociclib | Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer | Active, not recruiting | CAN | 0 |
NCT02906605 | Phase II | Apalutamide Apalutamide + JNJ-64041809 | A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer | Withdrawn | USA | 0 |
NCT02913196 | Phase I | Abiraterone + Apalutamide + Docetaxel + Prednisone | Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC | Active, not recruiting | USA | 0 |
NCT02923180 | Phase I | MGA271 | Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer | Active, not recruiting | USA | 0 |
NCT02949284 | Phase II | Apalutamide Abiraterone + Apalutamide + Prednisone | Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery | Recruiting | USA | 0 |
NCT02952534 | Phase II | Rucaparib | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON2) | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 3 |
NCT02975934 | Phase III | Rucaparib Docetaxel Enzalutamide Abiraterone | A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 3 |
NCT02987829 | Phase Ib/II | TRC253 | A Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients | Completed | USA | 0 |
NCT02991911 | Phase I | Enzalutamide + MEDI3726 MEDI3726 | A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer | Completed | USA | GBR | 1 |
NCT02995330 | Phase I | Cyclophosphamide + Filgrastim + Mycophenolate mofetil + Tacrolimus + Testosterone cypionate Cyclophosphamide + Fludarabine | Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer | Terminated | USA | 0 |
NCT03007732 | Phase II | Pembrolizumab + SD-101 Pembrolizumab | Pembrolizumab in Combination With Intratumoral SD-101 Therapy | Active, not recruiting | USA | 0 |
NCT03009981 | Phase III | Abiraterone + Apalutamide + Degarelix + Prednisone Apalutamide + Degarelix Degarelix | A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer | Active, not recruiting | USA | 0 |
NCT03012321 | Phase II | Abiraterone + Olaparib + Prednisone Abiraterone + Prednisone Olaparib | Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects | Unknown status | USA | 0 |
NCT03016312 | Phase III | Atezolizumab + Enzalutamide Enzalutamide | IMbassador250: A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 11 |
NCT03024216 | Phase I | Atezolizumab + Sipuleucel-T | Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients Who Have Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer | Completed | USA | 0 |
NCT03030885 | Phase I | 131I-MIP-1095 | Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Completed | USA | 0 |
NCT03042468 | Phase I | lutetium Lu 177 vipivotide tetraxetan | Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC | Active, not recruiting | USA | 0 |
NCT03043807 | Phase II | Bicalutamide + Docetaxel + Leuprolide | A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy | Completed | USA | 0 |
NCT03047135 | Phase II | Olaparib | Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis | Recruiting | USA | 0 |
NCT03061539 | Phase II | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature | Active, not recruiting | GBR | 0 |
NCT03070886 | Phase III | Bicalutamide + Docetaxel + Flutamide + Goserelin + Leuprolide + Nilutamide Bicalutamide + Flutamide + Goserelin + Leuprolide + Nilutamide | Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery | Active, not recruiting | USA | CAN | 1 |
NCT03072238 | Phase III | Abiraterone Abiraterone + Ipatasertib | Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer | Active, not recruiting | USA | ITA | GBR | FRA | ESP | CAN | BEL | AUT | AUS | 17 |
NCT03076203 | Phase I | Niraparib + Radium Ra 223 dichloride | Radium Ra 223 Dichloride and Niraparib in Treating Patients With Hormone- Resistant Prostate Cancer Metastatic to the Bone | Completed | USA | 0 |
NCT03080116 | Phase II | Degarelix Apalutamide + Degarelix | Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy (ARNEO) | Unknown status | BEL | 0 |
NCT03085095 | Phase III | Relugolix Leuprolide | A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer (HERO) | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 12 |
NCT03093272 | Phase II | Leuprolide Prednisone Apalutamide + Docetaxel | A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer | Terminated | USA | 0 |
NCT03093428 | Phase II | Pembrolizumab + Radium Ra 223 dichloride Radium Ra 223 dichloride | Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC | Active, not recruiting | USA | 0 |
NCT03098836 | Phase II | Abiraterone + Apalutamide + Prednisone | Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer | Active, not recruiting | USA | 0 |
NCT03147196 | Phase II | Bicalutamide + Raloxifene Raloxifene Bicalutamide | Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery | Withdrawn | 0 | |
NCT03148795 | Phase II | Talazoparib | A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer | Completed | USA | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS | 5 |
NCT03150056 | Phase I | Abiraterone + Molibresib Enzalutamide + Molibresib Prednisone | Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer | Terminated | USA | GBR | ESP | AUS | 0 |
NCT03177187 | Phase Ib/II | AZD5069 + Enzalutamide | Combination Study of AZD5069 and Enzalutamide. (ACE) | Active, not recruiting | GBR | 1 |
NCT03177460 | Phase I | Daratumumab Edicotinib | Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer | Active, not recruiting | USA | 0 |
NCT03204812 | Phase II | Durvalumab + Tremelimumab | Tremelimumab + Durvalumab Chemotherapy Naive CRPC | Completed | USA | 0 |
NCT03248570 | Phase II | Pembrolizumab | Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects | Active, not recruiting | USA | 0 |
NCT03262103 | Phase I | Poly ICLC | Neoadjuvant Hiltonol (PolyICLC) for Prostate Cancer | Completed | USA | 0 |
NCT03276572 | Phase I | 225Ac-J591 | Phase I Trial of 225Ac-J591 in Patients With mCRPC | Active, not recruiting | USA | 0 |
NCT03279250 | Phase II | Goserelin Triptorelin Abiraterone + Apalutamide + Prednisone Leuprolide Apalutamide | Effects of Apalutamide Plus LHRH Agonist or Apalutamide Plus Abiraterone Acetate Plus LHRH Agonist for Six Months for Prostate Cancer Patients at High Risk for Recurrence | Completed | USA | 0 |
NCT03298087 | Phase II | Abiraterone + Apalutamide + Leuprolide | Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer | Active, not recruiting | USA | 0 |
NCT03300505 | Phase Ib/II | AZD5312 + Enzalutamide | ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer | Terminated | USA | 0 |
NCT03317392 | Phase Ib/II | Olaparib | Olaparib and Radium Ra 223 Dichloride in Treating Men With Metastatic Castration-Resistant Prostate Cancer That Has Spread to the Bone | Recruiting | USA | 0 |
NCT03338790 | Phase II | Enzalutamide + Nivolumab Nivolumab + Rucaparib Docetaxel + Nivolumab | An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer | Active, not recruiting | USA | FRA | ESP | DEU | CAN | AUS | 5 |
NCT03360721 | Phase II | Abiraterone + Apalutamide + Prednisone | Study of Apalutamide and Abiraterone Acetate in Castration-Resistant Bone Metastatic Prostate Cancer Patients | Suspended | USA | 0 |
NCT03361735 | Phase II | Leuprolide + Radium Ra 223 dichloride Goserelin + Radium Ra 223 dichloride | Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer | Recruiting | USA | 0 |
NCT03365791 | Phase II | Ieramilimab Spartalizumab | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | Completed | USA | 0 |
NCT03371719 | Phase II | Apalutamide | Radiation Therapy With or Without Apalutamide in Treating Patients With Stage III-IV Prostate Cancer | Active, not recruiting | USA | CAN | 0 |
NCT03385655 | Phase II | Savolitinib Darolutamide Adavosertib | Prostate Cancer Biomarker Enrichment and Treatment Selection | Recruiting | CAN | 0 |
NCT03395197 | Phase III | Talazoparib | Talazoparib + NHT vs. NHT Monotherapy in DDR+ mCRPC (TALAPRO-2) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 17 |
NCT03406858 | Phase II | Pembrolizumab | Pembrolizumab and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer | Completed | USA | 0 |
NCT03412396 | Phase II | Apalutamide | Single Arm Study of 6-Months Neoadjuvant ARN-509 Prior to Radical Prostatectomy | Active, not recruiting | USA | 0 |
NCT03413995 | Phase II | Rucaparib | Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations (TRIUMPH) | Recruiting | USA | 0 |
NCT03414034 | Phase II | Abiraterone + Onvansertib + Prednisone | PCM-075 in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer | Active, not recruiting | USA | 0 |
NCT03419234 | Phase II | Abiraterone + Prednisone Abiraterone + Cabazitaxel + Prednisone | Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Hormone-Sensitive Prostate Cancer Previously Treated With Docetaxel | Active, not recruiting | USA | 1 |
NCT03431350 | Phase Ib/II | Cetrelimab + Niraparib | A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer | Active, not recruiting | USA | ITA | GBR | ESP | CAN | BEL | 1 |
NCT03432897 | Phase II | Olaparib | BrUOG 337: Olaparib Prior to Radical Prostatectomy For Patients With Locally Advanced Prostate Cancer and Defects in DNA Repair Genes (337) | Terminated | USA | 0 |
NCT03436654 | Phase II | Abiraterone + Apalutamide + Prednisone | A Study of Hormonal Therapy and Apalutamide With or Without Abiraterone Acetate and Prednisone in Newly Diagnosed Prostate Cancers | Recruiting | USA | 0 |
NCT03437941 | Phase Ib/II | CORT125281 + Enzalutamide | Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC | Completed | USA | GBR | 0 |
NCT03442556 | Phase II | Carboplatin + Docetaxel + Rucaparib | Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency | Active, not recruiting | USA | 0 |
NCT03456804 | Phase II | CEP-11981 | ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer | Active, not recruiting | USA | 0 |
NCT03458247 | Phase II | Abiraterone | Study of Dose Escalation of Abiraterone Actetate in Prostate Cancer (OPTIMABI) | Completed | FRA | 0 |
NCT03465345 | Phase I | Metformin + OPC | Study of Metformin Plus Oligomeric Procyanidin Complex for Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients | Withdrawn | USA | 0 |
NCT03480646 | Phase Ib/II | Enzalutamide Abiraterone + CPI-1205 + Prednisone CPI-1205 + Enzalutamide | ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer | Active, not recruiting | USA | 0 |
NCT03503344 | Phase II | Apalutamide | Apalutamide With or Without Stereotactic Body Radiation Therapy in Treating Participants With Castration-Resistant Prostate Cancer (PILLAR) | Recruiting | USA | 0 |
NCT03506997 | Phase II | Pembrolizumab | Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (PERSEUS1) | Recruiting | GBR | 0 |
NCT03511196 | Phase I | Abiraterone + Prednisone Leuprolide Goserelin Triptorelin | Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer | Active, not recruiting | USA | 0 |
NCT03516812 | Phase II | Olaparib + Testosterone Enanthate | Testosterone Enanthate and Olaparib in Treating Participants With Castration-Resistant Prostate Cancer | Active, not recruiting | USA | 0 |
NCT03517488 | Phase I | XmAb20717 | A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) | Completed | USA | 0 |
NCT03532217 | Phase I | Ipilimumab + Nivolumab + PROSTVAC-F-TRICOM + PROSTVAC-V-TRICOM | Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer | Completed | USA | 0 |
NCT03533946 | Phase II | Rucaparib | Rucaparib in Nonmetastatic prOstAte With BRCAness (ROAR) | Active, not recruiting | USA | 0 |
NCT03541928 | Phase II | Bicalutamide + HSV-Tk + Leuprolide + Valacyclovir | Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery | Recruiting | USA | 0 |
NCT03545165 | Phase Ib/II | 177Lu-J591 + lutetium Lu 177 vipivotide tetraxetan | 177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC | Terminated | USA | 0 |
NCT03551782 | Phase I | Apalutamide + Cetrelimab | A Study of JNJ-63723283, a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer | Completed | USA | ITA | ESP | CAN | BEL | 2 |
NCT03554317 | Phase II | Nivolumab + Testosterone cypionate | COMbination of Bipolar Androgen Therapy and Nivolumab | Completed | USA | 0 |
NCT03556904 | Phase II | Abiraterone + Docetaxel + Enzalutamide | FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE) | Active, not recruiting | USA | 0 |
NCT03565835 | Phase II | Abiraterone + Prednisone | Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer | Active, not recruiting | USA | 0 |
NCT03570476 | Phase II | Olaparib | Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer | Terminated | USA | 0 |
NCT03570619 | Phase II | Ipilimumab + Nivolumab | Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations (IMPACT) | Active, not recruiting | USA | 0 |
NCT03572387 | Phase II | Azacitidine + Leuprolide + Tretinoin | A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment | Completed | USA | 0 |
NCT03577028 | Phase I | HPN424 | Study of HPN424 in Patients With Advanced Prostate Cancer | Active, not recruiting | USA | GBR | 0 |
NCT03579654 | Phase II | Proscavax | Study of Proscavax Vaccine in Patients With Localized Prostate Cancer vs Active Surveillance | Unknown status | USA | 0 |
NCT03600350 | Phase II | Nivolumab + pTVG-HP plasmid DNA vaccine + Sargramostim | pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer | Active, not recruiting | USA | 0 |
NCT03637543 | Phase II | Nivolumab | Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer | Recruiting | USA | 0 |
NCT03649841 | Phase II | Abiraterone + Prednisone Abiraterone + Prednisone + Radiotherapy | Effects of Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Radiation on Prostate Cancer | Terminated | USA | 0 |
NCT03678025 | Phase III | Docetaxel Nilutamide Triptorelin Bicalutamide Leuprolide Degarelix Goserelin Flutamide Prednisone Abiraterone Histrelin acetate | Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | Recruiting | USA | 2 |
NCT03686683 | Phase III | Sipuleucel-T | Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer (ProVent) | Active, not recruiting | USA | 0 |
NCT03690141 | Phase II | Tomivosertib | A Study Examining the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC) | Completed | USA | 0 |
NCT03693612 | Phase Ib/II | GSK3359609 + Tremelimumab Paclitaxel Docetaxel Cetuximab | GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors | Completed | USA | CAN | AUS | 0 |
NCT03706365 | Phase II | Abemaciclib + Abiraterone + Prednisone Abiraterone + Prednisone | A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer | Active, not recruiting | USA | GBR | FRA | ESP | DEU | AUS | 6 |
NCT03712930 | Phase II | Pamiparib | Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency | Terminated | USA | ESP | AUS | 1 |
NCT03724747 | Phase I | BAY 2315497 | Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Anti-tumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Metastatic Castration Resistant Prostate Cancer | Active, not recruiting | USA | GBR | 1 |
NCT03725761 | Phase II | Sacituzumab govitecan-hziy | IMMU-132 in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy | Recruiting | USA | 0 |
NCT03732820 | Phase III | Abiraterone Abiraterone + Olaparib | Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 8 |
NCT03734653 | Phase I | Enzalutamide + Testosterone | Testosterone Therapy in Castration Resistant Prostate Cancer | Recruiting | USA | 0 |
NCT03748641 | Phase III | Abiraterone + Niraparib + Prednisone Abiraterone + Prednisone | A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 20 |
NCT03753243 | Phase II | Enzalutamide + Pembrolizumab | Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer | Recruiting | USA | 0 |
NCT03767244 | Phase III | Apalutamide Abiraterone + Apalutamide Prednisone | A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 10 |
NCT03770455 | Phase II | Avelumab + Enzalutamide Abiraterone + Avelumab | Phase II Trial of Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC | Terminated | USA | 0 |
NCT03787680 | Phase II | Ceralasertib + Olaparib | Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial) | Active, not recruiting | USA | 0 |
NCT03805594 | Phase I | lutetium Lu 177 vipivotide tetraxetan + Pembrolizumab | 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | Active, not recruiting | USA | 0 |
NCT03809000 | Phase II | Goserelin Bicalutamide Enzalutamide Leuprolide | A Trial to See What the Results Are for Radiation Therapy and Hormone Therapy vs Radiation Therapy With Enhanced Hormone Therapy With Enzalutamide for Patients With PSA Recurrence After Surgery (STEEL) | Active, not recruiting | USA | CAN | 0 |
NCT03821246 | Phase II | Atezolizumab + Emactuzumab Atezolizumab Atezolizumab + Enzalutamide | Neoadjuvant Atezolizumab With or Without Enzalutamide in Localized Prostate Cancer Given Before Radical Prostatectomy | Recruiting | USA | 0 |
NCT03821792 | Phase II | Abiraterone + Apalutamide + Prednisone | Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer | Active, not recruiting | USA | 0 |
NCT03827473 | Phase II | Abiraterone + Prednisone Docetaxel | Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer (ACADEMIC) | Terminated | USA | 0 |
NCT03829930 | Phase I | Entinostat + Enzalutamide | Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer | Terminated | USA | 0 |
NCT03833921 | Phase II | Abiraterone + Prednisone | Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer (APRE) | Recruiting | USA | 0 |
NCT03834493 | Phase III | Enzalutamide + Pembrolizumab Enzalutamide | Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS | 19 |
NCT03834506 | Phase III | Docetaxel + Prednisone Dexamethasone + Docetaxel + Pembrolizumab + Prednisone | Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS | 12 |
NCT03834519 | Phase III | Abiraterone + Prednisone Enzalutamide Olaparib + Pembrolizumab | Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) (KEYLYNK-010) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS | 11 |
NCT03837353 | Phase Ib/II | DKN-01 DKN-01 + Docetaxel | A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1 | Terminated | USA | 0 |
NCT03840200 | Phase Ib/II | Ipatasertib + Rucaparib | A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer. | Completed | USA | ITA | ESP | AUS | 1 |
NCT03861403 | Phase Ib/II | Avelumab + Cyclophosphamide + TRX518 | A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors | Terminated | USA | 0 |
NCT03874884 | Phase I | lutetium Lu 177 vipivotide tetraxetan + Olaparib | 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer (LuPARP) | Recruiting | AUS | 0 |
NCT03886493 | Phase II | Dupilumab | Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer | Terminated | USA | 0 |
NCT03888612 | Phase I | ARV-110 | A Phase 1 Clinical Trial of ARV-110 in Patients With Metastatic Castration-resistant Prostate Cancer. (mCRPC) | Recruiting | USA | 0 |
NCT03899077 | Phase II | Triptorelin Goserelin Degarelix Leuprolide Apalutamide | Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP (SAVE) | Recruiting | BEL | 0 |
NCT03899987 | Phase II | Aspirin + Rintatolimod Aspirin + Interferon alpha-2b + Rintatolimod | Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery | Suspended | USA | 0 |
NCT03902951 | Phase II | Abiraterone + Apalutamide + Leuprolide | Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer | Active, not recruiting | USA | 0 |
NCT03903835 | Phase III | Docetaxel Cabazitaxel Carboplatin Abiraterone Enzalutamide | ProBio: A Biomarker Driven Study in Patients With Metastatic Castrate Resistant Prostate Cancer (ProBio) | Recruiting | BEL | 3 |
NCT03926013 | Phase I | JNJ-63898081 | A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumors | Completed | USA | CAN | 0 |
NCT03939689 | Phase II | Enzalutamide 131I-MIP-1095 + Enzalutamide | Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone (ARROW) | Active, not recruiting | USA | CAN | 0 |
NCT03964337 | Phase II | Cabozantinib | Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer (SPARC) | Terminated | USA | 0 |
NCT03972657 | Phase Ib/II | Cemiplimab + REGN5678 | Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer | Recruiting | USA | 0 |
NCT03999515 | Phase II | Enzalutamide + Erdafitinib Abiraterone + Erdafitinib | Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer | Recruiting | USA | 0 |
NCT04015622 | Phase II | Docetaxel Enzalutamide | PROTRACT (PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA) STUDY (PROTRACT) | Recruiting | CAN | 0 |
NCT04019327 | Phase Ib/II | Talazoparib + Temozolomide | A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer | Recruiting | USA | 0 |
NCT04025372 | Phase II | Bicalutamide Darolutamide | INTREPId (INTermediate Risk Erection PreservatIon Trial) | Recruiting | USA | 0 |
NCT04033328 | Phase I | Enzalutamide + ORIC-101 | Study of ORIC-101 in Combination With Enzalutamide | Active, not recruiting | USA | 0 |
NCT04033432 | Phase II | sEphB4-HSA | sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | Active, not recruiting | USA | 0 |
NCT04037254 | Phase II | Niraparib | Niraparib With Standard Combination Radiation Therapy and Androgen Deprivation Therapy in Treating Patients With High Risk Prostate Cancer | Recruiting | USA | CAN | 0 |
NCT04060394 | Phase Ib/II | Afuresertib + LAE001 + Prednisone Afuresertib | Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC | Active, not recruiting | USA | 1 |
NCT04070209 | Phase II | Darolutamide | Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X) | Recruiting | CAN | 0 |
NCT04077021 | Phase I | CCW702 | First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer | Terminated | USA | 0 |
NCT04090528 | Phase II | Pembrolizumab + pTVG-AR + pTVG-HP plasmid DNA vaccine + Sargramostim Pembrolizumab + pTVG-HP plasmid DNA vaccine + Sargramostim | pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer | Recruiting | USA | 0 |
NCT04090775 | Phase II | Cyclophosphamide + Ipilimumab + Nivolumab | A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma | Completed | USA | 0 |
NCT04097002 | Phase Ib/II | ORCA-010 | First in Man Clinical Study to Evaluate Safety and Tolerability of an Oncolytic Adenovirus in Prostate Cancer Patients. | Recruiting | CAN | 0 |
NCT04100018 | Phase III | Docetaxel + Nivolumab + Prednisone Docetaxel + Prednisone | A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer (CheckMate 7DX) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 18 |
NCT04104893 | Phase II | Pembrolizumab | A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation (CHOMP) | Recruiting | USA | 0 |
NCT04109729 | Phase Ib/II | Nivolumab + Radium Ra 223 dichloride | Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer (Rad2Nivo) | Recruiting | USA | 0 |
NCT04116775 | Phase II | Enzalutamide + Pembrolizumab | Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer. | Recruiting | USA | 0 |
NCT04126070 | Phase II | Docetaxel + Nivolumab Leuprolide Goserelin Degarelix | Nivolumab + Docetaxel + ADT in Metastatic Hormone Sensitive Prostate Cancer | Recruiting | USA | 0 |
NCT04134260 | Phase III | Abiraterone + Apalutamide + Prednisone | Testing the Addition of the Drugs, Apalutamide and Abiraterone Acetate With Prednisone, to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer | Recruiting | USA | 0 |
NCT04136353 | Phase III | Darolutamide | Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (DASL-HiCaP) | Recruiting | USA | GBR | CAN | AUS | 2 |
NCT04157088 | Phase II | Enzalutamide Darolutamide | Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC) (DaroAcT) | Completed | USA | 0 |
NCT04175431 | Phase II | Abiraterone + Prednisone | Fluciclovine (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study | Recruiting | USA | 0 |
NCT04176081 | Phase II | Darolutamide + Degarelix | Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer (SChLAP/IDC) | Not yet recruiting | CAN | 0 |
NCT04179396 | Phase I | Enzalutamide + Rucaparib Abiraterone + Rucaparib | Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP) (RAMP) | Active, not recruiting | USA | 0 |
NCT04179864 | Phase I | Enzalutamide + Tazemetostat Abiraterone + Prednisone + Tazemetostat | A Phase 1b/2 Open-Label Study in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer | Active, not recruiting | USA | ESP | BEL | 0 |
NCT04181203 | Phase III | Gonadorelin + Radiotherapy Apalutamide + Gonadorelin + Radiotherapy | Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy (CARLHA-2) | Recruiting | FRA | 0 |
NCT04191096 | Phase III | Enzalutamide + Pembrolizumab Enzalutamide | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS | 20 |
NCT04194554 | Phase Ib/II | Abiraterone + Leuprolide + Niraparib + Prednisone | A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer (ASCLEPIuS) | Recruiting | USA | 0 |
NCT04207255 | Phase II | ABC294640 + Enzalutamide ABC294640 + Abiraterone | Addition of Opaganib to Androgen Antagonists in Patients With mCRPC | Active, not recruiting | USA | 0 |
NCT04237584 | Phase III | Darolutamide Darolutamide + Radium Ra 223 dichloride Enzalutamide Enzalutamide + Radium Ra 223 dichloride | A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients (ESCALATE) | Terminated | USA | 0 |
NCT04262154 | Phase II | Abiraterone + Atezolizumab + Leuprolide + Prednisone | Study of Abiraterone Acetate, Atezolizumab, Lupron, and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer | Recruiting | USA | 0 |
NCT04272645 | Phase II | Abemaciclib + Atezolizumab Abemaciclib Atezolizumab | Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer | Withdrawn | USA | 0 |
NCT04288687 | Phase II | Niraparib | A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects | Recruiting | USA | 0 |
NCT04291664 | Phase I | Abiraterone + Prednisone DST-2970 + Prednisone | PK and Dose Escalation and Expansion Study of DST-2970 | Active, not recruiting | USA | 0 |
NCT04295447 | Phase II | Apalutamide | Adjuvant Apalutamide in Subjects With High-risk Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy (ADAM) | Recruiting | DEU | AUT | 0 |
NCT04296578 | Phase I | Abiraterone + Prednisone + Sodium Selenite | Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone | Withdrawn | 0 | |
NCT04298983 | Phase II | Abemaciclib | Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer (RAD 1805) | Recruiting | USA | 0 |
NCT04301414 | Phase I | BMS-986218 + Degarelix Degarelix | Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer (Neo-Red-P) | Active, not recruiting | USA | 0 |
NCT04319783 | Phase II | Darolutamide | Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA (DECREASE) | Recruiting | AUS | 0 |
NCT04331717 | Phase II | Leuprolide | Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer (BASH-PC) | Withdrawn | USA | 0 |
NCT04332744 | Phase II | Enzalutamide + Talazoparib Enzalutamide | Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First) (ZZ-First) | Recruiting | ESP | 0 |
NCT04335682 | Phase II | Darolutamide Enzalutamide | Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide | Recruiting | USA | 0 |
NCT04336943 | Phase II | Durvalumab + Olaparib | Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load | Recruiting | USA | 0 |
NCT04343885 | Phase II | Docetaxel Docetaxel + lutetium Lu 177 vipivotide tetraxetan | In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy (UpFrontPSMA) | Recruiting | AUS | 0 |
NCT04363164 | Phase II | Testosterone Enanthate Testosterone cypionate Enzalutamide | Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression | Recruiting | USA | 0 |
NCT04382898 | Phase Ib/II | BNT112 + Cemiplimab BNT112 | PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy) (PRO-MERIT) | Recruiting | USA | GBR | DEU | 1 |
NCT04393298 | Phase Ib/II | UCB6114 Trifluridine-tipiracil hydrochloride + UCB6114 Fluorouracil + Leucovorin + Oxaliplatin + UCB6114 | A Study to Assess the Safety, Pharmacokinetics and Antitumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors | Recruiting | USA | GBR | 0 |
NCT04397276 | Phase I | JNJ-70218902 | A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors | Active, not recruiting | ESP | CAN | 1 |
NCT04404140 | Phase I | Atezolizumab + Docetaxel + Ipatasertib | A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC). | Completed | ITA | FRA | ESP | 1 |
NCT04419402 | Phase II | Enzalutamide + lutetium Lu 177 vipivotide tetraxetan Enzalutamide | Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer (ENZA-p) | Recruiting | AUS | 0 |
NCT04423211 | Phase III | Apalutamide + Leuprolide Apalutamide + Goserelin Leuprolide Goserelin | Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Using PET/CT Imaging | Recruiting | USA | 0 |
NCT04428203 | Phase I | Cannabidiol | Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer | Completed | USA | 0 |
NCT04428788 | Phase I | CC-94676 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | 0 |
NCT04430192 | Phase Ib/II | lutetium Lu 177 vipivotide tetraxetan | Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy (LuTectomy) | Active, not recruiting | AUS | 0 |
NCT04446117 | Phase III | Enzalutamide Atezolizumab + Cabozantinib Abiraterone + Prednisone | Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 17 |
NCT04455750 | Phase III | Enzalutamide Goserelin + Leuprolide Enzalutamide + Rucaparib Degarelix | A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy (CASPAR) | Recruiting | USA | 0 |
NCT04458311 | Phase Ib/II | Abiraterone + Tildrakizumab | Abiraterone Acetate in Combination With Tildrakizumab (ACTIon) | Recruiting | GBR | 1 |
NCT04471974 | Phase II | Enzalutamide + Pembrolizumab + ZEN-3694 | ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | 0 |
NCT04493853 | Phase III | Abiraterone + Capivasertib Abiraterone | Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency (CAPItello-281) | Recruiting | USA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 24 |
NCT04495179 | Phase II | AZD4635 + Durvalumab AZD4635 + Cabazitaxel + Durvalumab | A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC. (AARDVARC) | Completed | USA | FRA | ESP | BEL | 1 |
NCT04497844 | Phase III | Abiraterone + Niraparib + Prednisone Abiraterone + Prednisone | A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (AMPLITUDE) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 24 |
NCT04506567 | Phase Ib/II | 225Ac-J591 | Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC | Recruiting | USA | 0 |
NCT04513717 | Phase III | Bicalutamide + Buserelin Buserelin + Flutamide Abiraterone + Apalutamide + Degarelix + Prednisone Abiraterone + Apalutamide + Buserelin + Prednisone Flutamide + Triptorelin Degarelix + Flutamide Abiraterone + Apalutamide + Leuprolide + Prednisone Flutamide + Leuprolide Flutamide + Goserelin Abiraterone + Apalutamide + Histrelin acetate + Prednisone Bicalutamide + Triptorelin Bicalutamide + Goserelin Flutamide + Histrelin acetate Bicalutamide + Degarelix Abiraterone + Apalutamide + Goserelin + Prednisone Abiraterone + Apalutamide + Prednisone + Triptorelin Bicalutamide + Leuprolide Bicalutamide + Histrelin acetate | Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial | Recruiting | USA | CAN | 0 |
NCT04523207 | Phase II | Apalutamide | A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases | Active, not recruiting | USA | 0 |
NCT04530552 | Phase II | Apalutamide | Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland | Recruiting | USA | 0 |
NCT04536805 | Phase Ib/II | Metformin | Relapse in Previously Irradiated Prostate Bed : Stereotactic Ablative Reirradiation Potentiated by Metformin (REPAIRGETUGP16) | Recruiting | FRA | 0 |
NCT04556617 | Phase Ib/II | Olaparib + PLX2853 Abiraterone + PLX2853 + Prednisone | PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Terminated | USA | GBR | 0 |
NCT04557059 | Phase III | Apalutamide + Triptorelin Triptorelin Apalutamide + Goserelin Apalutamide + Leuprolide Leuprolide Goserelin | A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Prostate-Specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) Positive Hormone-Sensitive Prostate Cancer Participants (PRIMORDIUM) | Recruiting | USA | ITA | ESP | BEL | AUT | AUS | 14 |
NCT04557449 | Phase I | Letrozole + PF-07220060 Fulvestrant + PF-07220060 PF-07220060 | Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4) | Recruiting | USA | GBR | 6 |
NCT04569461 | Phase II | Pembrolizumab | Trimodality Approach to Localized Prostate Cancer: Pembrolizumab, ADT, and SBRT Followed by Prostatectomy (TALON) | Not yet recruiting | USA | 0 |
NCT04576871 | Phase I | 225Ac-J591 | Re-treatment 225Ac-J591 for mCRPC | Recruiting | USA | 0 |
NCT04577833 | Phase I | Abiraterone + Niraparib + Prednisone | A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer | Active, not recruiting | USA | GBR | FRA | ESP | BEL | 6 |
NCT04628988 | Phase I | Abiraterone + CC-90011 + Prednisone | A Study of CC-90011 and Comparators in Participants With Prostate Cancer | Active, not recruiting | USA | 0 |
NCT04631601 | Phase I | AMG 160 + AMG 404 AMG 160 + Enzalutamide Abiraterone + AMG 160 AMG 404 | Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC) | Active, not recruiting | USA | GBR | ESP | AUS | 2 |
NCT04635059 | Phase II | Pacritinib | Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer (BLAST) | Recruiting | USA | 0 |
NCT04641078 | Phase II | Darolutamide | Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer (DART) | Recruiting | BEL | 0 |
NCT04647526 | Phase III | Abiraterone + Dexamethasone Abiraterone + Prednisone Enzalutamide PNT2002 | Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH) | Recruiting | USA | GBR | FRA | CAN | 2 |
NCT04655365 | Phase II | Enzalutamide | Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer. (PROSTEP-002) | Recruiting | CAN | 0 |
NCT04662580 | Phase I | ARX517 | ARX517 in Subjects With Advanced Solid Tumor (ARX517) | Recruiting | USA | 0 |
NCT04666129 | Phase I | Abiraterone + Prednisone + Relugolix | Study of Relugolix in Men With High-Risk Metastatic Castration-Sensitive Prostate Cancer or Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | 0 |
NCT04689828 | Phase III | lutetium Lu 177 vipivotide tetraxetan | 177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer | Active, not recruiting | USA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | 6 |
NCT04691804 | Phase III | Abiraterone + Fluzoparib + Prednisone Abiraterone + Prednisone | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | GBR | FRA | ESP | BEL | AUS | 7 |
NCT04709276 | Phase II | Cabazitaxel + Carboplatin + Ipilimumab + Nivolumab | A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (CHAMP) | Active, not recruiting | USA | 0 |
NCT04720157 | Phase III | lutetium Lu 177 vipivotide tetraxetan | An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Soc, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition) | Recruiting | USA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | 13 |
NCT04726332 | Phase I | Abiraterone + Prednisone + XL102 Fulvestrant + XL102 XL102 | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) | Recruiting | USA | 0 |
NCT04734730 | Phase II | Abiraterone + Bicalutamide + Leuprolide + Prednisone + Talazoparib Abiraterone + Goserelin + Prednisone + Talazoparib Abiraterone + Degarelix + Prednisone + Talazoparib | Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer | Recruiting | USA | 0 |
NCT04736199 | Phase III | Darolutamide | Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer (ARANOTE) | Active, not recruiting | ESP | CAN | AUS | 12 |
NCT04740034 | Phase I | AMG 340 | A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma | Recruiting | USA | 0 |
NCT04748042 | Phase II | Abiraterone + Olaparib + Prednisone | Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON) | Recruiting | USA | 0 |
NCT04751929 | Phase II | Abemaciclib + Atezolizumab Atezolizumab Abemaciclib | Abemaciclib With or Without Atezolizumab for mCRPC | Recruiting | USA | 0 |
NCT04754191 | Phase II | Enfortumab vedotin-ejfv | Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer (ENCORE) | Recruiting | USA | 0 |
NCT04754425 | Phase II | Erdafitinib | Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer | Recruiting | USA | 0 |
NCT04781374 | Phase II | Neratinib | Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer | Withdrawn | USA | 0 |
NCT04812366 | Phase II | Abiraterone + Apalutamide + Prednisone Apalutamide Abiraterone + Prednisone Apalutamide + Atezolizumab Abiraterone + Docetaxel + Prednisone Abiraterone + Niraparib + Prednisone | Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer (GUNS) | Recruiting | USA | CAN | 0 |
NCT04821622 | Phase III | Enzalutamide Enzalutamide + Talazoparib | Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 18 |
NCT04824937 | Phase II | Talazoparib + Telaglenastat | Telaglenastat + Talazoparib In Prostate Cancer | Unknown status | USA | 0 |
NCT04844749 | Phase III | Abiraterone Enzalutamide VERU-111 | Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent (VERU-111) | Active, not recruiting | USA | 0 |
NCT04886986 | Phase Ib/II | 225Ac-J591 + PNT2002 | 225Ac-J591 Plus 177Lu-PSMA-I&T for mCRPC | Recruiting | USA | 0 |
NCT04887506 | Phase III | Abiraterone + Prednisone Prednisone + TAVT-45 | TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer | Completed | USA | GBR | FRA | ESP | 4 |
NCT04898634 | Phase I | JNJ-78278343 | A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer | Recruiting | USA | FRA | ESP | 1 |
NCT04916613 | Phase III | Darolutamide | ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Unfit) | Recruiting | FRA | ESP | BEL | 1 |
NCT04925284 | Phase I | XB002 Nivolumab + XB002 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | Recruiting | USA | 0 |
NCT04925648 | Phase II | Darolutamide + Dasatinib Dasatinib | Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction (PICASSO) | Recruiting | AUS | 0 |
NCT04926181 | Phase II | Apalutamide + Cetrelimab | Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer | Recruiting | USA | 0 |
NCT04931979 | Phase II | Pembrolizumab | SRT in Combination With Pembrolizumab in Patients With Recurrent Prostate Cancer After Radical Prostatectomy (Pembro-SRT) | Recruiting | DEU | 0 |
NCT04946370 | Phase Ib/II | Pembrolizumab 225Ac-J591 + Pembrolizumab | Maximizing Responses to Anti-PD1 Immunotherapy With PSMA-targeted Alpha Therapy in mCRPC | Recruiting | USA | 0 |
NCT04951492 | Phase II | Olaparib | Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma | Recruiting | USA | 0 |
NCT04989946 | Phase Ib/II | Degarelix Degarelix + Nivolumab + pTVG-AR Degarelix + pTVG-AR | Androgen Deprivation, With or Without pTVG-AR, and With or Without Nivolumab, in Patients With Newly Diagnosed, High-Risk Prostate Cancer | Recruiting | USA | 0 |
NCT05010200 | Phase I | CDX-301 + PGV 001 + Poly ICLC PGV 001 + Poly ICLC | The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting. (PGV-Prostate) | Recruiting | USA | 0 |
NCT05011188 | Phase Ib/II | Enzalutamide + FOR46 | FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer | Recruiting | USA | 0 |
NCT05011383 | Phase II | Testosterone | High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers (VA-BAT) | Recruiting | USA | 0 |
NCT05019846 | Phase III | Bicalutamide + Triptorelin | SRT Versus SRT+ADT in Prostate Cancer (SPA) | Recruiting | ITA | 0 |
NCT05022849 | Phase I | JNJ-75229414 | A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants | Active, not recruiting | USA | 0 |
NCT05050084 | Phase III | Buserelin Relugolix Degarelix Goserelin Leuprolide Histrelin acetate Triptorelin Darolutamide + Goserelin Bicalutamide Darolutamide + Degarelix Darolutamide + Leuprolide Darolutamide + Triptorelin Buserelin + Darolutamide Darolutamide + Histrelin acetate Flutamide Darolutamide + Relugolix | Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score | Recruiting | USA | CAN | 0 |
NCT05053152 | Phase II | Relugolix | Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer (NRG PROMETHEAN) | Recruiting | USA | 0 |
NCT05059236 | Phase II | Darolutamide | A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study. (ARASEC) | Recruiting | USA | 0 |
NCT05075577 | Phase Ib/II | Enzalutamide + EPI-7386 Enzalutamide | EPI-7386 in Combination With Enzalutamide Compared With Enzalutamide Alone in Subjects With mCRPC | Recruiting | USA | CAN | 0 |
NCT05077098 | Phase I | ADXS-504 | Study of ADXS-504 Immunotherapy for Recurrent Prostate Cancer | Recruiting | USA | 0 |
NCT05079698 | Phase I | lutetium Lu 177 vipivotide tetraxetan | A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer | Active, not recruiting | USA | 0 |
NCT05081193 | Phase II | Enzalutamide + Testosterone | Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer | Recruiting | USA | 0 |
NCT05100472 | Phase II | Bicalutamide + Leuprolide | A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer | Recruiting | USA | 0 |
NCT05110495 | Phase I | Xentuzumab | Windows Trial of INsulin-like Growth Factor Neutralising Antibody Xentuzumab in MEN Scheduled for Radical Prostatectomy (WINGMEN) | Active, not recruiting | GBR | 0 |
NCT05124795 | Phase I | IMU-935 | IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer | Recruiting | GBR | 0 |
NCT05125016 | Phase Ib/II | REGN4336 Cemiplimab + REGN4336 | REGN4336 (a PSMAXCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Adult Male Patients With Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | 0 |
NCT05150236 | Phase II | Ipilimumab + lutetium Lu 177 vipivotide tetraxetan + Nivolumab lutetium Lu 177 vipivotide tetraxetan Nivolumab | 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC (EVOLUTION) (EVOLUTION) | Recruiting | AUS | 0 |
NCT05156905 | Phase II | Cirmtuzumab + Docetaxel | Phase 2 Trial of Docetaxel Combined With Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer | Recruiting | USA | 0 |
NCT05168618 | Phase II | Atezolizumab + Cabozantinib | Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial | Recruiting | USA | 0 |
NCT05176483 | Phase I | Nivolumab + NKTR-214 XL092 Nivolumab + NKTR-214 + XL092 Ipilimumab + Nivolumab + XL092 Nivolumab + XL092 Ipilimumab + Nivolumab | Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors (STELLAR-002) | Recruiting | USA | ITA | ESP | BEL | AUT | AUS | 4 |
NCT05177042 | Phase I | Abiraterone + ARV-110 | Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | Recruiting | USA | GBR | FRA | CAN | 0 |
NCT05204927 | Phase III | Abiraterone + Enzalutamide lutetium Lu 177 vipivotide tetraxetan Abiraterone + Prednisone | Lu-177-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | ITA | FRA | ESP | 0 |
NCT05230251 | Phase II | PNT2002 | Radioligand fOr locAl raDiorecurrent proStaTe cancER (ROADSTER) | Recruiting | CAN | 0 |
NCT05252364 | Phase I | HP518 | A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer | Recruiting | AUS | 0 |
NCT05288166 | Phase III | Abiraterone + Prednisone Abemaciclib + Abiraterone + Prednisone | A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) (CYCLONE 3) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 16 |
NCT05295927 | Phase I | Apalutamide + EPI-7386 Abiraterone + EPI-7386 + Prednisone | A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) | Terminated | USA | CAN | 0 |
NCT05340374 | Phase Ib/II | Cabazitaxel + lutetium Lu 177 vipivotide tetraxetan | Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer (LuCAB) | Recruiting | AUS | 0 |
NCT05348577 | Phase III | Capivasertib + Docetaxel Docetaxel | Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC) (CAPItello-280) | Recruiting | USA | GBR | FRA | ESP | CAN | BEL | AUS | 15 |
NCT05393791 | Phase II | Abiraterone + Enzalutamide | Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC (ANZadapt) | Recruiting | AUS | 1 |
NCT05404139 | Phase II | Enzalutamide | Duration of Enzalutamide and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT) | Recruiting | CAN | 0 |
NCT05422911 | Phase II | Enzalutamide Abiraterone Apalutamide | Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer. | Not yet recruiting | USA | 0 |
NCT05425862 | Phase I | CX-5461 + Talazoparib | Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer (REPAIR) | Recruiting | AUS | 0 |
NCT05441501 | Phase I | JNJ-80038114 | A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer | Recruiting | USA | GBR | 0 |
NCT05445609 | Phase II | Nivolumab + Vidutolimod | Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer | Not yet recruiting | USA | 0 |
NCT05496959 | Phase II | PNT2002 | 177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study (LUNAR) | Recruiting | USA | 0 |
NCT05498272 | Phase II | Leuprolide + Olaparib Goserelin + Olaparib Olaparib + Triptorelin | Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations (NePtune) | Recruiting | USA | 0 |
NCT05502315 | Phase II | Cabozantinib + Nivolumab | Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer (CANOPY) | Recruiting | USA | 0 |
NCT05519449 | Phase I | JANX007 | Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) | Recruiting | USA | AUS | 0 |
NCT05526248 | Phase II | Enzalutamide Darolutamide | A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide (ARAMON) | Recruiting | USA | 0 |
NCT05551117 | Phase II | Enzalutamide Abiraterone MGC018 | MGC018 Versus Androgen Receptor Axis-targeted Therapy in Participants With Metastatic Castration Resistant Prostate Cancer (Tamarack) | Recruiting | USA | GBR | FRA | ESP | BEL | AUS | 1 |
NCT05563558 | Phase II | Cabazitaxel + Carboplatin + Pembrolizumab | Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS) (PEAPOD_FOS) | Recruiting | ESP | 0 |
NCT05568550 | Phase II | Pembrolizumab Olaparib + Pembrolizumab | Pembro With Radiation With or Without Olaparib | Not yet recruiting | USA | 0 |
NCT05585034 | Phase I | Pembrolizumab + XmAb808 | Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb808 in Combination With Pembrolizumab in Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05588609 | Phase II | Enzalutamide + Zenocutuzumab Afatinib + Zenocutuzumab Abiraterone + Zenocutuzumab | Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers | Recruiting | USA | 0 |
NCT05593497 | Phase II | Abiraterone + Capivasertib | A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss (SNARE) | Not yet recruiting | USA | 0 |
NCT05613894 | Phase I | Cabozantinib + lutetium Lu 177 vipivotide tetraxetan | Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer (CaboLu) | Not yet recruiting | USA | 0 |
NCT05617885 | Phase Ib/II | Abemaciclib + Darolutamide + Degarelix + Goserelin + Leuprolide Darolutamide + Degarelix + Goserelin + Leuprolide | Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer | Not yet recruiting | USA | 0 |
NCT05620914 | Phase I | Patritumab deruxtecan | A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases (PARAMETer) | Not yet recruiting | USA | 0 |
NCT05646550 | Phase I | CC-1 | Antibody CC-1 in Men With Biochemical Recurrence of Prostate Cancer (ProSperACC-1) | Recruiting | DEU | 0 |
NCT05676203 | Phase III | Darolutamide + Docetaxel | A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients (ARASAFE) | Recruiting | DEU | 0 |
NCT05689021 | Phase II | CJNJ-67652000 + Prednisone | CJNJ-67652000 and Prednisone for the Treatment of Men With Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations | Not yet recruiting | USA | 0 |
NCT05691465 | Phase II | lutetium Lu 177 dotatate | Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells | Recruiting | USA | 0 |
NCT05700669 | Phase Ib/II | AsiDNA + Olaparib | Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors | Recruiting | USA | 0 |
NCT05719558 | Phase I | ASP1002 | A Study of ASP1002 in Adults for Treatment of Solid Tumors | Recruiting | USA | 0 |
NCT05733351 | Phase I | Abiraterone + XmAb20717 Enzalutamide + XmAb20717 Abiraterone + Docetaxel + XmAb20717 | Vudalimab in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer | Not yet recruiting | USA | 0 |
NCT05766371 | Phase II | lutetium Lu 177 vipivotide tetraxetan + Pembrolizumab | Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer | Not yet recruiting | USA | 0 |
NCT05794906 | Phase III | Darolutamide | A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Nonmetastatic Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies (ARASTEP) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS | 9 |
NCT05800665 | Phase I | RO7656594 | A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer | Recruiting | USA | AUS | 0 |
NCT05818683 | Phase I | Cetrelimab + JNJ-78278343 | A Study of JNJ-78278343 in Combination With JNJ-63723283 (Cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | 0 |
NCT05826509 | Phase II | Darolutamide | SUrGery With or Without dARolutamide in High-risk and/or Locally Advanced Prostate Cancer (SUGAR) | Not yet recruiting | FRA | 0 |
NCT05841563 | Phase I | PM54 | Clinical Trial of PM54 in Advance Solid Tumors Patients. | Recruiting | USA | ESP | BEL | 0 |
NCT05884398 | Phase III | Apalutamide | A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC (LIBERTAS) | Not yet recruiting | USA | DEU | 0 |